We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $875B
1-Year Est. Return 40.91%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
-13.42%
1 Year Est. Return
+40.91%
3 Year Est. Return
+115.85%
5 Year Est. Return
+132.1%
10 Year Est. Return
+518.81%
AUM
$390B
AUM Growth
-$94.7B
Cap. Flow
+$10.4B
Cap. Flow %
2.66%
Top 10 Hldgs %
28.21%
Holding
14,957
New
1,520
Increased
5,503
Reduced
5,522
Closed
2,191

Sector Composition

Rank Sector Weight
1 Healthcare 2.83%
2 Technology 2.79%
3 Financials 2.29%
4 Consumer Discretionary 1.93%
5 Industrials 1.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RJAC.WS
11376
DELISTED
Jackson Acquisition Company Redeemable Warrants, each whole warrant exercisable for one share of Class A common stock at an exercise price of $11.50
RJAC.WS
$94K ﹤0.01%
624,615
-1,264
-0.2% -$234
CANE icon
11377
PUT
Teucrium Sugar Fund
CANE
$53.5M
$93K ﹤0.01%
10,000
-5,300
-35% -$51.2K
CRNT icon
11378
Ceragon Networks
CRNT
$200M
$93K ﹤0.01%
36,342
-54,039
-60% -$103K
GLDI icon
11379
Credit Suisse X-Links Gold Shares Covered Call ETNs due February 2 2033
GLDI
$32.7M
$93K ﹤0.01%
+597
New +$97.2K
KXIN icon
11380
Kaixin Holdings
KXIN
$8.43M
0
LTRX icon
11381
Lantronix
LTRX
$289M
$93K ﹤0.01%
17,366
+82
+0.5% +$473
NAUT icon
11382
Nautilus Biotechnolgy
NAUT
$114M
$93K ﹤0.01%
34,650
-23,815
-41% -$88.6K
OXBR icon
11383
Oxbridge Re Holdings
OXBR
$12.4M
$93K ﹤0.01%
+27,843
New +$132K
HTT
11384
High Templar Tech Ltd
HTT
$393M
$93K ﹤0.01%
84,432
-184,942
-69% -$180K
SOND
11385
CALL
DELISTED
Sonder
SOND
$93K ﹤0.01%
4,485
-215
-5% -$12.2K
TNXP icon
11386
Tonix Pharmaceuticals
TNXP
$218M
$93K ﹤0.01%
+3
New +$221K
ABST
11387
CALL
DELISTED
Absolute Software Corp
ABST
$93K ﹤0.01%
10,800
-400
-4% -$3.35K
WMC
11388
DELISTED
Western Asset Mortgage Capital Corporation
WMC
$93K ﹤0.01%
7,719
-2,151
-22% -$29.1K
BLND icon
11389
CALL
Blend Labs
BLND
$352M
$92K ﹤0.01%
39,100
-98,000
-71% -$366K
ERNA icon
11390
CALL
Eterna Therapeutics
ERNA
$4.98M
$92K ﹤0.01%
24
+10
+71% +$71.8K
LTBR icon
11391
Lightbridge
LTBR
$317M
$92K ﹤0.01%
+19,635
New +$124K
ROIV icon
11392
PUT
Roivant Sciences
ROIV
$26.1B
$92K ﹤0.01%
+22,700
New +$90.1K
WATT icon
11393
CALL
Energous
WATT
$86M
$92K ﹤0.01%
154
+39
+34% +$23.7K
IRAAW
11394
DELISTED
Iris Acquisition Corp Warrant
IRAAW
$92K ﹤0.01%
681,871
-201,808
-23% -$71.5K
TCON
11395
CALL
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$92K ﹤0.01%
2,290
-6,470
-74% -$250K
EWEB
11396
DELISTED
Global X Emerging Markets Internet & E-commerce ETF
EWEB
$92K ﹤0.01%
+4,055
New +$87.9K
CHMI
11397
CALL
Cherry Hill Mortgage Investment Corp
CHMI
$108M
$91K ﹤0.01%
+14,200
New +$97.8K
MTA
11398
CALL
Metalla Royalty & Streaming
MTA
$912M
$91K ﹤0.01%
18,900
-33,600
-64% -$196K
OCGN icon
11399
Ocugen
OCGN
$458M
$91K ﹤0.01%
40,002
-36,499
-48% -$87.3K
TBPH icon
11400
CALL
Theravance Biopharma
TBPH
$881M
$91K ﹤0.01%
10,000
-12,200
-55% -$112K

Similar funds

Ken Griffin's Q2 2022 Portfolio in Review

As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.

By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.

  • Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
  • Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
  • Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
  • Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
  • Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
  • Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
  • Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.